Corient Private Wealth
AQST icon

Corient Private Wealth’s Aquestive Therapeutics AQST Stock Holding History

Corient Private Wealth’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-95,813
Closed -$249K – 2462
2024
Q2 		$249K Hold
95,813
– – ﹤0.01% 2011
2024
Q1 		$408K Sell
95,813
-95,813
-50% -$319K ﹤0.01% 1731
2023
Q4 		$387K Sell
191,626
-265,700
-58% -$470K ﹤0.01% 1743
2023
Q3 		$700K Buy
+457,326
New +$786K ﹤0.01% 1322

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return

Corient Private Wealth's AQST Position: Q3 2024 in Review

Corient Private Wealth sold out of Aquestive Therapeutics (AQST) in Q3 2024, closing a stake of 95,813 shares — an estimated $249K sold.

Corient Private Wealth first reported a position in AQST in Q3 2023 and held it in 4 quarters. The position peaked at $700K in Q3 2023. 117 funds tracked by Wall St. Rank hold AQST as of Q3 2024.

  • Corient Private Wealth reported no remaining Aquestive Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Corient Private Wealth sold 95,813 Aquestive Therapeutics shares in Q3 2024, an estimated $249K.
  • Corient Private Wealth first reported a position in Aquestive Therapeutics in Q3 2023 and held it in 4 quarters.
  • Corient Private Wealth's Aquestive Therapeutics position peaked at $700K in Q3 2023.
  • 117 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2024.

Based on Corient Private Wealth's 13F filing for Q3 2024, filed 12 Nov 2024.